Denmark offers great prices on medicine

Denmark is one of Europe’s most competitive nations when it comes to the availability and cost of generic drugs. A recent study by the European Commission found that competitive pricing and convenient access to generic drugs was keeping the costs low in Denmark.

The study discovered that the prices for medicine within the EU are so high because the pharmaceutical companies relentlessly battle against generic drug manufacturers, and nations occasionally sign deals that limit competition. Problems with regulation, such as the absence of a unified EU patent along with lengthy procedures for generic drugs approval, are creating unnecessarily high prices for medicine.

Denmark’s pricing policy, on the other hand, requires chemists to select drugs that are the least expensive to ensure generic medicine gets into the market quickly and effectively. Denmark also enjoys healthy competition between local producers of generic drugs, all to the benefit of the customer’s pocketbook.

“In Denmark the authorities have pursued a wise pricing policy because our subsidy system ensures that only the cheapest drugs are selected at the pharmacy,” commented Kjeld Moller Pedersen, a health economist and professor at the University of Southern Denmark, to the Copenhagen Post.

Within the EU it’s a different story. It’s a cutthroat industry where lawsuits and backroom deals take a higher priority over consideration for the health and finances of the individual. But EU officials are beginning to examine whether some of the methods used by the pharmaceutical industry are in fact legal and fair to their citizens.

See the full article at CPHPost.

Comments are closed.